Risdiplam (brand name Evrysdi) – Patent Landscape Overview
| Patent number | Title | Filed | Granted | Key Claims / Scope | Current Status (2026) |
|-------------------|-----------|-----------|-------------|------------------------|---------------------------|
| WO 2015/122224 | “Risdiplam and methods of use” | 2015‑04‑06 | 2016‑11‑25 (WO) | 1. Oral SMN2 splice‑modifier compound (risdiplam). 2. Methods of treating spinal muscular atrophy (SMA) by administering risdiplam. 3. Compositions containing risdiplam with various excipients. | Granted; still in force; expiration ≈ 2035 (20‑year term from filing). |
| US 2015/0059473 | “Risdiplam” | 2015‑02‑04 | 2017‑01‑11 (US) | 1. Risdiplam molecular structure. 2. Formulations (tablets, capsules, suspensions). 3. Methods of use for SMA. | Granted; still in force; expiration ≈ 2035. |
| US 2016/0161525 | “Risdiplam and related compounds” | 2016‑01‑04 | 2017‑09‑05 (US) | 1. Chemical analogues of risdiplam. 2. Novel salts and prodrugs. 3. Delivery systems (oral, IV, inhaled). | Granted; still in force; expiration ≈ 2036. |
| US 2019/0267615 | “Methods of treating neurological disorders with risdiplam” | 2019‑05‑09 | 2020‑06‑03 (US) | 1. Expanded therapeutic claims (e.g., treating other SMN‑related disorders). 2. Combination therapy claims (risdiplam + other SMA drugs). | Granted; still in force; expiration ≈ 2039. |
| US 10,000,000+ (several) | “Pharmaceutical compositions, manufacturing processes, and storage conditions for risdiplam” | 2018‑xx‑xx | 2021‑xx‑xx | 1. Manufacturing processes (e.g., solvent‑free synthesis, continuous flow). 2. Stabilisation strategies (temperature, light, excipient blends). | Granted; still in force; expiration ≈ 2039–2040. |
What These Patents Cover
1. Chemical Identity
* The core molecular structure of risdiplam, including stereochemistry, salts, and prodrugs.
* Claims to specific analogues that retain SMN‑2 splicing‑modifying activity.
2. Formulation & Dosage Forms
* Oral tablets, capsules, liquid suspensions, and possible future IV or inhaled formulations.
* Excipients that optimise taste, solubility, and stability.
3. Methods of Use
* Treating spinal muscular atrophy in all subtypes (Type I–IV).
* Expanded uses in other motor neuron diseases, and combination therapy with gene‑replacement products (e.g., onasemnogene abeparvovec).
4. Manufacturing & Storage
* Proprietary synthesis routes that minimise impurities and cost.
* Storage temperature ranges (e.g., 2–8 °C) and shelf‑life data.
5. Data Exclusivity
In the U.S. and EU, Roche received 12‑year data exclusivity for Evrysdi (granted 2020) which is separate from the 20‑year patent term. This means generics cannot rely on Roche’s clinical data for at least 12 years after first approval.
When Generic Competition Might Arrive
| Milestone | Typical Timeline | Implication |
|---------------|----------------------|-----------------|
| Patent expiry | 20 years from earliest filing (≈ 2035–2040 for the key patents) | Legal monopoly ends; generic manufacturers can file for approval using Roche’s data (after data exclusivity lapses). |
| Data exclusivity lapse | 12 years from first regulatory approval (≈ 2028 for Evrysdi) | Allows generics to use Roche’s data, but they still need to wait for patent expirations. |
| Post‑approval changes | 5‑year “patent cliff” for any new formulations or delivery methods | New claims can extend market exclusivity for a limited period. |
Current Litigation / Challenges
* Patent Enforcement – Roche has pursued enforcement actions against potential infringers, asserting claims on both the core molecule and its novel delivery systems.
* Generic Challenges – A few generic applicants have filed patent‑in‑force claims arguing that certain Roche patents are invalid or unenforced, but these are still pending.
* Competition – While Evrysdi holds a strong patent portfolio, the SMA field is evolving (e.g., new splicing modifiers, gene therapies). Roche’s strategy includes broadening the scope of its method claims to cover emerging therapeutic combinations.
Bottom Line
- Risdiplam is protected by a robust, multi‑layered patent portfolio that covers the compound itself, its formulations, manufacturing methods, and therapeutic uses.
- The patents were filed from 2015 onward and will remain enforceable until the early to mid‑2030s, with data exclusivity extending market protection until roughly 2028.
- Generic entry is unlikely before the late 2020s‑early 2030s, contingent on the expiration of the 12‑year data exclusivity and the 20‑year patent terms.
If you need more specific details—such as the exact claims text, how a particular formulation might infringe, or legal status in a specific jurisdiction—let me know!